Webcast ImageWebcast
Guggenheim Healthcare Talks Idea Forum Oncology Day Adaptimmune Therapeutics (Replay)
02/14/19 at 10:00 a.m. ET
Guggenheim Healthcare Talks Idea Forum Oncology Day Adaptimmune Therapeutics
Thursday, February 14, 2019 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Adaptimmune Q4 / Full Year 2018 Financial Results and Business Update (Live)
02/27/19 at 8:00 a.m. ET
Adaptimmune Q4 / Full Year 2018 Financial Results and Business Update
Wednesday, February 27, 2019 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Adaptimmune at 8th Annual Leerink Global Healthcare Conference (Live)
02/28/19 at 10:00 a.m. ET
Adaptimmune at 8th Annual Leerink Global Healthcare Conference
Thursday, February 28, 2019 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/07/19Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S. markets open on Wednesday, February 27, 2019. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day. The press release and the ... 
Printer Friendly Version
01/07/19Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort. The SRC has also endorsed moving to the expansion phase of the ADP-A2M10 (MAGE-A10) lung cancer study. Across both studies, mos... 
Printer Friendly Version